Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Gynecologic Oncology
•
Medical Oncology
•
Survivorship
•
Genetics
•
Breast Cancer, Non-metastatic
•
Sexual Health
•
Primary Care
Would you consider HRT after risk-reducing salpingo-oophorectomy for a young (mid-30s) patient with BRCA1 and a history of TNBC?
Related Questions
Do you follow LFTs in patients on tamoxifen as suggested in the prescribing guidelines?
Do you recommend self-breast exams to your patients with history of breast cancer in addition to imaging surveillance?
What is your preferred method of surveillance after mastectomy?
Is 5fx APBI and no endocrine therapy a new standard of care for women over 70 years old with low-risk breast cancer given the interim analysis of the EUROPA trial?
How do you treat high-risk inflammatory TNBC diagnosed in the first trimester of pregnancy who underwent surgery?
When do you recommend preoperative chemotherapy or hormonal therapy for ER+ breast cancer?
How do you approach early-stage breast cancer patients who are asking for ctDNA or tumor marker surveillance (or previously receiving these with another provider) when these are not part of the NCCN or ASCO guidelines?
What is the preferred duration of adjuvant aromatase inhibitor therapy in patients with triple positive breast cancer?
How would you approach surveillance imaging for men with early-stage, hormone receptor-positive breast cancer after unilateral mastectomy?
What adjuvant therapy would you recommend for a premenopausal woman with low ER+/PR+ (1-10%) HER2- pT1cN0 metaplastic breast cancer?
